GEN reports on ocular therapeutics targeting the retina

Genetic Engineering & Biotechnology News cover image. GEN is published 21 times per year. Credit: ©2012, Mary Ann Liebert, Inc., publishers

Therapies for retinal diseases are expected to overtake those for glaucoma by 2014, reports Genetic Engineering & Biotechnology News (GEN). Because current retinal disease treatments only improve vision for six to eight weeks, there is a critical need for new remedies, according to a recent issue of GEN.

"As increasing numbers of baby-boomers continue to grow older, many will have to deal with eye diseases such as age-related macular degeneration," said John Sterling, Editor-in-Chief of GEN. "Some estimates put the current AMD and diabetic retinopathy drug segment of the market at $3 billion, and this is expected to increase to about $5 billion in two years."

Standard therapy has been Genentech's VEGF inhibitors Lucentis and the off-label use of Avastin®. Regeneron, in collaboration with Bayer HealthCare, is challenging these drugs with a similar VEGF inhibitor, Eyela. The FDA approved the drug last November for wet AMD.

In another approach, Acucela is in Phase II trials using visual cycle modulators to lighten the metabolic load on the retina by reducing the activity of the rod visual system. This protects the retina from light damage, improves retinal vasculature, and reduces the accumulation of A2E and other retinal-related toxic by-products.

GlaxoSmithKline has two drugs in Phase II trials for ocular therapy: darapladib, an oral Lp-PLA2 inhibitor for diabetic macular edema, and Votrient®, a multi-kinase angiogenesis inhibitor in eye drop form for AMD. Early-stage work also is under way for neovascular AMD, dry AMD, diabetic retinopathy, diabetic macula edema, uveitis, and , as well as for technologies for drug delivery.

add to favorites email to friend print save as pdf

Related Stories

FDA approves drug to treat diabetic macular edema

Aug 13, 2012

The U.S. Food and Drug Administration today announced its approval of Lucentis (ranibizumab injection) for the treatment of diabetic macular edema, or DME, an eye condition in people with diabetes that causes blurred vision, ...

Recommended for you

Hygiene practices affect contact lens case contamination

Jan 28, 2015

Contact lens wearers who don't follow certain hygiene habits have increased bacterial contamination of their contact lens cases, reports a study in the February issue of Optometry and Vision Science, official journal of the ...

Team creates device to alleviate dry eye

Jan 26, 2015

A search for medical needs in eye clinics led Stanford Biodesign fellows to develop an implantable neurostimulator that painlessly increases natural tear production.

Scientists discover gene tied to profound vision loss

Jan 16, 2015

An exhaustive hereditary analysis of a large Louisiana family with vision issues has uncovered a new gene tied to an incurable eye disorder called retinitis pigmentosa, according to an examination led by ...

User comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.